US, EU Grant Accelerated Reviews Of Merck & Co., Inc. Hepatitis Drug
DOW JONES NEWSWIRES -- Merck & Co. (MRK) said Thursday U.S. and European regulators have granted expedited reviews of its experimental hepatitis C drug, heating up a race with Vertex Pharmaceuticals Inc. (VRTX) and its partner Johnson & Johnson (JNJ) to bring the next new treatment to a potentially lucrative market.